A Study of LP-118 in Patients With Advanced Tumors
Study Details
Study Description
Brief Summary
This is a phase I, multi-center, open-label, dose escalation study to evaluate the safety, tolerability, pharmacokinetics and clinical activity of LP-118 in patients with advanced malignancies, including solid tumors and B-cell lymphomas. LP-118 is a BCL-2/BCL-XL small molecule inhibitor.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 1 |
Detailed Description
LP-118 is an oral selective BCL-2 inhibitor with tuned BCL-XL activity, aiming to improve antitumor efficacy and reduce the risk of thrombocytopenia. Clinical development of LP-118 includes targeting of relapsed or refractory hematological malignancies and solid tumors. This is a multi-center, open-label, Phase 1 dose escalation study of LP-118 in patients with advanced malignancies, including advanced/metastatic solid tumors and relapsed/refractory B-cell lymphomas, to determine the safety, tolerability, pharmacokinetics profile and preliminary anti-tumor efficacy. Upon completion of the Phase 1 dose escalation study and establishment of maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D), the dose expansion study will be implemented in patients with protocol designated type of disease.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: LP-118 An "accelerated titration" for the first two dose cohorts (50mg and 100mg) followed by classic "3+3" design for the rest of dose cohorts (200mg, 300mg, 400mg and 500mg) will be used in this study. |
Drug: LP-118 tablet
Subjects will administered orally with LP-118 tablet at the designated dose once daily, using approximately 240 mL of water during a meal or within 30 minutes after a meal, 28 days per cycle. The treatment will continue until progressive disease, unacceptable toxicity, etc.
Other Names:
|
Outcome Measures
Primary Outcome Measures
- Maximum tolerated dose (MTD) [Up to 24 months]
The highest dose that does not cause unacceptable side effects or overt toxicities which will be assessed by NCI CTCAE v5.0.
- Adverse events [Up to 24 months]
The incidence and severity of adverse events as assessed by NCI CTCAE v5.0.
- Recommended phase II dose (RP2D) [Up to 24 months]
The safe dose that demonstrates the greatest pharmacological activity.
- PK evaluation of area under the plasma concentration versus time curve (AUC) of LP-118 [Up to Cycle 6 (each cycle is 28 days)]
AUC indicates the extent of exposure to LP-118 and its clearance rate from the body.
- PK evaluation of peak plasma concentration (Cmax) of LP-118 [Up to Cycle 6 (each cycle is 28 days)]
Cmax indicates the highest drug concentration in the blood after LP-118 administration.
- PK evaluation of time to maximum concentration (Tmax) of LP-118 [Up to Cycle 6 (each cycle is 28 days)]
Tmax indicates the time taken to reach the maximum drug concentration (i.e. Cmax).
Secondary Outcome Measures
- Overall response rate (ORR) [Up to 24 months]
The proportion of patients who have a partial or complete response after LP-118 treatment.
- Duration of response (DOR) [Up to 24 months]
The time from first documented response to disease progression or death.
- Progression-free survival (PFS) [Up to 24 months]
The time from first dose to disease progression or death, whichever occurs first.
- Overall survival [Up to 24 months]
The time from first dose to the date of death from any cause.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Subjects with histologically or cytologically confirmed malignancy, including either of the following disease: relapsed or refractory B-cell lymphoma with at least one measurable disease based on Lugano 2014 criteria; or advanced or metastatic solid tumors based on RECIST V1.1 criteria.
-
Subjects have a life expectancy of ≥12 weeks, and Eastern Cooperative Oncology Group (ECOG) performance score less than or equal to 1.
-
Subjects must have adequate bone marrow function independent of blood transfusion or growth factor support per local laboratory reference range at Screening.
-
Subjects must have adequate coagulation, renal, and hepatic function, per local laboratory reference range at Screening.
-
All acute toxicity from previous anti-tumor treatment or surgery has been alleviated to NCI CTCAE 5.0 ≤ Grade 1.
-
All enrolled subjects should take medically approved contraceptives during the entire treatment period and within 90 days after the end of treatment.
-
Volunteer and sign informed consent, willing to follow trial protocol.
Exclusion Criteria:
-
Subjects who have undergone allogeneic or autologous hematopoietic stem cell transplantation (except for lymphoma patients who had received autologous stem cell transplantation before 90 days of the first dose of LP-118).
-
Subjects who have received the following treatments within 4 weeks or 5 half-lives before the first dose of study drug:
-
Antitumor therapies including myelosuppressive chemotherapy, targeted therapy, biological therapy and/or immunotherapy;
-
Any investigational treatment;
-
Patients who have undergone major surgery, severe trauma or radiotherapy.
-
Subjects who have received the following treatments within 1 week before the first dose of study drug:
-
Steroids or traditional herbal medicine for antitumor purposes;
-
Strong and moderate CYP3A inhibitors and inducers, grapefruit and grapefruit juice;
-
Any medications that can cause QTc interval prolongation or torsional tachycardia.
-
Solid tumor patients with ITP or AIHA.
-
Subjects with known bleeding disease or with a history of non-chemotherapy induced thrombocytopenic bleeding or ineffective platelet transfusion within 1 year before the first dose of study drug.
-
Subjects with uncontrollable or CTCAE ≥ grade 2 gastrointestinal bleeding occurred within 90 days before the first dose of study drug.
-
Subjects have received the therapeutic dose of anticoagulant or antiplatelet drugs within 1 week before the first dose of study drug.
-
Subjects have any serious and/or uncontrolled systemic disease.
-
Subjects have poor cardiovascular function, in line with New York Heart Association (NYHA) cardiac function classification ≥ 2 or QTcF greater than 450ms (male) or 470ms (female) on ≥ 3 independent ECG.
-
Subjects have disease states where clinical manifestations may be difficult to control, including but not limited to HIV, HBV, HCV, syphilis positive or active bacterial and fungal infections.
-
Lymphoma with primary central nervous system (CNS) malignancy or any disease affects the CNS.
-
Any gastrointestinal conditions that may severely affect the study drug absorption or pharmacokinetic parameters.
-
Subjects who have known severe allergies to study drugs or any excipients.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Guangdong Provincial People's Hospital | Guangzhou | Guangdong | China | 510080 |
Sponsors and Collaborators
- Guangzhou Lupeng Pharmaceutical Company LTD.
Investigators
- Study Chair: Yilong Wu, MD, Guangdong Provincial People's Hospital
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- LP-118-CN101